skip to Main Content

Dr. Pant on Choosing Therapy for Frontline and Beyond in Pancreatic Cancer

Newsfeed image, light gray text on dark gray background

Treatment for patients with pancreatic cancer need to be selected on an individual level. Typically, the 2 frontline regimens are modified FOLFIRINOX or the combination of gemcitabine and nab-paclitaxel (Abraxane). FOLFIRINOX is typically used in more robust patients with a better performance status whereas gemcitabine/nab-paclitaxel is used in patients who have a performance status of 2. Read more . . . 

Back To Top